Regulatory compliance through QbD and PAT

Nov. 16, 2011 - PRLog -- One of the biggest concerns for all businesses is ensuring they remain compliant with industry regulations and, in the pharmaceutical sector particularly, failure to comply with legislation can lead to the cancellation of projects and big business losses.

It is a constant struggle for firms in this industry to continuously adapt to regulatory changes, including rules published by the US Food and Drug Administration (FDA), but this is vital if they are to remain competitive and maintain their market share. However, it is the rapidly changing regulatory backdrop that has led to the development of Quality by Design (QbD) processes which are focused on tightening quality and safety in production in response to variations, with reliance on process analytical technology (PAT). This method has been proven to cut costs and increase efficiency by improving overall quality – a main aim of all organisations.

The 9th Annual PAT and Quality by Design event will be hosted from 20 - 22 February, 2012 in London. For more details, visit the 9th Annual PAT and Quality by Design website, call freephone: 0800 652 2363 or email: enquire@iqpc.co.uk.

To download this article in full please click here:
http://www.iqpc.com/Event.aspx?id=602050&utm_campaign=Helen &utm_medium=HWOnline&utm_source=PR Log&MAC=HW_PROMO_11287.006_PR